{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:47Z","timestamp":1786982747904,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40257-022-00703-1","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T07:02:41Z","timestamp":1655967761000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-6081","authenticated-orcid":false,"given":"Mette","family":"Gyldenl\u00f8ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Alinaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"703_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509\u201319. https:\/\/doi.org\/10.1111\/bjd.16102.","journal-title":"Br J Dermatol"},{"key":"703_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","volume":"151","author":"AW Armstrong","year":"2015","unstructured":"Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151:432\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3456.","journal-title":"JAMA Dermatol"},{"issue":"135\u201344","key":"703_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.027","volume":"79","author":"AM Loos","year":"2018","unstructured":"Loos AM, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2018;79(135\u201344): e7. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.027.","journal-title":"J Am Acad Dermatol"},{"key":"703_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archdermatol.2007.28","volume":"144","author":"JK Robinson","year":"2008","unstructured":"Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144:97\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2007.28.","journal-title":"Arch Dermatol"},{"key":"703_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1203475416631328","volume":"20","author":"M AbuHilal","year":"2016","unstructured":"AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016;20:313\u20136. https:\/\/doi.org\/10.1177\/1203475416631328.","journal-title":"J Cutan Med Surg"},{"key":"703_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/2475530318788934","volume":"3","author":"A Alomran","year":"2018","unstructured":"Alomran A, Zancanaro P, Prussick L, et al. Apremilast in combination with an interleukin 17A inhibitor in the treatment of recalcitrant palmoplantar psoriasis: a chart review. J Psoriasis Psoriatic Arthritis. 2018;3:122\u20135.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"703_CR8","doi-asserted-by":"crossref","unstructured":"Arag\u00f3n-Miguel R, Gonz\u00e1lez IM, Gonz\u00e1lez-Valle O, Arag\u00f3n-D\u00edez A. Combination therapy of apremilast and biologic agent as a step-up strategy option of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 83(6 supplement) (abstract) 2020.","DOI":"10.1016\/j.jaad.2020.06.337"},{"key":"703_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14464","volume":"33","author":"S Armesto","year":"2020","unstructured":"Armesto S, Gonzalez Vela C, Sanchez J, et al. Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatol Ther. 2020;33: e14464. https:\/\/doi.org\/10.1111\/dth.14464.","journal-title":"Dermatol Ther"},{"key":"703_CR10","doi-asserted-by":"publisher","unstructured":"Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015;21. https:\/\/doi.org\/10.5070\/D3216027825.","DOI":"10.5070\/D3216027825"},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/ijd.IJD_548_18","volume":"64","author":"A De","year":"2019","unstructured":"De A, Das S, Dhoot D, Sarda A. Apremilast coadministered with Secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic. Indian J Dermatol. 2019;64:239\u201341. https:\/\/doi.org\/10.4103\/ijd.IJD_548_18.","journal-title":"Indian J Dermatol"},{"key":"703_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40291-018-0354-8","volume":"22","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, D\u2019Adamio S, Campione E, et al. Treating a multidrug-resistant psoriatic HLA-C*18:01 allele carrier with combination Ustekinumab Apremilast therapy. Mol Diagn Ther. 2018;22:717\u201321. https:\/\/doi.org\/10.1007\/s40291-018-0354-8.","journal-title":"Mol Diagn Ther"},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/1203475417712499","volume":"21","author":"JR Georgakopoulos","year":"2017","unstructured":"Georgakopoulos JR, Ighani A, Yeung J. Short- and long-term management of an acute pustular psoriasis flare: a case report. J Cutan Med Surg. 2017;21:452\u20136. https:\/\/doi.org\/10.1177\/1203475417712499.","journal-title":"J Cutan Med Surg"},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/247553031700200203","volume":"2","author":"A Hadi","year":"2017","unstructured":"Hadi A, Lebwohl M. Secukinumab and apremilast combination therapy for recalcitrant psoriasis. J Psoriasis Psoriatic Arthritis. 2017;2:59\u201361.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jaad.2018.04.043","volume":"79","author":"A Ighani","year":"2018","unstructured":"Ighani A, Georgakopoulos JR, Shear NH, et al. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: a multicenter, retrospective study. J Am Acad Dermatol. 2018;79:953\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2018.04.043.","journal-title":"J Am Acad Dermatol"},{"key":"703_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.09.060","volume":"78","author":"A Ighani","year":"2018","unstructured":"Ighani A, Georgakopoulos JR, Walsh S, et al. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2018;78:623\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.060.","journal-title":"J Am Acad Dermatol"},{"key":"703_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/1346-8138.14617","volume":"45","author":"M Kishimoto","year":"2018","unstructured":"Kishimoto M, Komine M, Hioki T, et al. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018;45:1345\u20138. https:\/\/doi.org\/10.1111\/1346-8138.14617.","journal-title":"J Dermatol"},{"key":"703_CR18","unstructured":"Masuda K, Kanehisa F, Katoh N. Combination therapy of apremilast and biological product in a patient with psoriasis. In: Acta dermato-venereologica conference 5th world psoriasis and psoriatic arthritis conference, p 392018."},{"key":"703_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.19104\/crcm.2016.128","volume":"2","author":"J Mayba","year":"2016","unstructured":"Mayba J, Gooderham M. Treatment of palmoplantar pustulosis with the combination of ustekinumab and apremilast: a case report. Arc Cas Rep CMed. 2016;2:128.","journal-title":"Arc Cas Rep CMed."},{"key":"703_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1573397115666181130094455","volume":"15","author":"S Metyas","year":"2019","unstructured":"Metyas S, Tomassian C, Messiah R, et al. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. Curr Rheumatol Rev. 2019;15:234\u20137. https:\/\/doi.org\/10.2174\/1573397115666181130094455.","journal-title":"Curr Rheumatol Rev"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/24755303","volume":"4","author":"AL Mikhailitchenko","year":"2019","unstructured":"Mikhailitchenko AL, Crowley EL, Gooderham M. Eight-patient case series of palmoplantar pustulosis treated successfully with apremilast. J Psoriasis Psoriatic Arthritis. 2019;4:7\u201310. https:\/\/doi.org\/10.1177\/24755303.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"703_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5152\/eurjrheum.2018.17188","volume":"6","author":"MK Nisar","year":"2019","unstructured":"Nisar MK. Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach. Eur J Rheumatol. 2019;6:60\u20131. https:\/\/doi.org\/10.5152\/eurjrheum.2018.17188.","journal-title":"Eur J Rheumatol"},{"key":"703_CR23","first-page":"648","volume":"15","author":"BE Rothstein","year":"2016","unstructured":"Rothstein BE, McQuade B, Greb JE, et al. Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis. J Drugs Dermatol. 2016;15:648\u20139.","journal-title":"J Drugs Dermatol"},{"key":"703_CR24","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/ced.14000","volume":"44","author":"L Sacchelli","year":"2019","unstructured":"Sacchelli L, Patrizi A, Loi C, Bardazzi F. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis. Clin Exp Dermatol. 2019;44:e243\u20134. https:\/\/doi.org\/10.1111\/ced.14000.","journal-title":"Clin Exp Dermatol"},{"key":"703_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/1346-8138.15193","volume":"47","author":"S Takamura","year":"2020","unstructured":"Takamura S, Sugai S, Taguchi R, Teraki Y. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. J Dermatol. 2020;47:290\u20134. https:\/\/doi.org\/10.1111\/1346-8138.15193.","journal-title":"J Dermatol"},{"issue":"310\u20137","key":"703_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052","volume":"77","author":"J Crowley","year":"2017","unstructured":"Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >\/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(310\u20137): e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052.","journal-title":"J Am Acad Dermatol"},{"key":"703_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/rheumatology\/kex454","volume":"57","author":"G Abignano","year":"2018","unstructured":"Abignano G, Fadl N, Merashli M, et al. Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. Rheumatology (Oxford). 2018;57:578\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/kex454.","journal-title":"Rheumatology (Oxford)"},{"key":"703_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.18981","volume":"183","author":"ZZN Yiu","year":"2020","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183:294\u2013302. https:\/\/doi.org\/10.1111\/bjd.18981.","journal-title":"Br J Dermatol"},{"key":"703_CR29","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.1021\/acs.jmedchem.9b02170","volume":"63","author":"T Peng","year":"2020","unstructured":"Peng T, Qi B, He J, et al. Advances in the development of phosphodiesterase-4 inhibitors. J Med Chem. 2020;63:10594\u2013617. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b02170.","journal-title":"J Med Chem"},{"key":"703_CR30","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28:753\u201363. https:\/\/doi.org\/10.1016\/j.cellsig.2016.01.007.","journal-title":"Cell Signal"},{"key":"703_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048. https:\/\/doi.org\/10.3389\/fphar.2018.01048.","journal-title":"Front Pharmacol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00703-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T22:19:32Z","timestamp":1662934772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00703-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00703-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"2 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Gyldenl\u00f8ve: None. F. Alinaghi: None. C. Zachariae: Investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, and LEO Pharma. Paid speaker for Eli Lilly, Novartis, CSL, and LEO Pharma. Consultant and\/or advisory board member for AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, Takeda, Amgen, and CSL. L. Skov: Received research funding from Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the LEO Foundation, and the Kgl Hofbundtmager Aage Bang Foundation. Honoraria as consultant and\/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, LEO Pharma, Janssen Cilag, UCB, Almirall, Bristol-Myers Squibb, and Sanofi. Investigator for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, Galderma, and LEO Pharma. A. Egeberg: Received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation. Honoraria as consultant and\/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Gal\u00e1pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, informed consent,\u00a0and code availability"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Conceptualization (MG), methodology (MG and FA), literature search and data extraction (MG, FA, and AE), resources (FA, CZ, and LS), writing\u2014original draft (MG), writing\u2014review and editing (FA, AE, LS, and CZ).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions (credit taxonomy)"}}]}}